 |
| 30-Nov-12 | Reiterated |
Stifel Nicolaus |
Buy |
$8 → $9 |
|
| 20-Apr-12 | Initiated |
Maxim Group |
Buy |
$9 |
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Buy |
$8 |
|
| 17-Aug-11 | Initiated |
Stifel Nicolaus |
Hold |
$8 |
|
| 18-Nov-09 | Downgrade |
Merriman |
Buy → Neutral |
|
|
| 17-Jun-09 | Initiated |
Boenning & Scattergood |
Neutral |
|
|
| 15-Dec-08 | Reiterated |
Lazard Capital |
Buy |
$7 → $8 |
|
| 24-Nov-08 | Reiterated |
Lazard Capital |
Buy |
$7 |
|
| 16-Oct-08 | Initiated |
Merriman Curhan Ford |
Buy |
|
|
| 14-Aug-08 | Initiated |
Banc of America Sec |
Neutral |
$7 |
|
| 06-Aug-08 | Reiterated |
Lazard Capital |
Buy |
$12 → $10 |
|
| 06-Aug-08 | Downgrade |
Canaccord Adams |
Buy → Hold |
|
|
| 08-Jul-08 | Initiated |
Canaccord Adams |
Buy |
$7.30 |
|
| 07-Dec-07 | Reiterated |
Fortis Bank |
Hold |
$10 → $9 |
|
| 14-Sep-07 | Initiated |
Lazard Capital |
Buy |
$14 |
|
| 04-Sep-07 | Downgrade |
Wachovia |
Outperform → Mkt Perform |
|
|
| 26-Jul-07 | Downgrade |
Stanford Research |
Buy → Hold |
|
|
|
|
| 21-May-13 12:05PM | Exelixis CEO Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha |
| 15-May-13 04:04PM | InPlay: Exelixis issues reminder that cabozantinib to be featured in nine presentations at 2013 ASCO Annual Meeting Briefing.com |
| 04:02PM | Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting Business Wire |
| 14-May-13 05:32PM | Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 01:04PM | EXELIXIS, INC. Financials EDGAR Online Financials |
| 12-May-13 06:06PM | Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? at Seeking Alpha |
| 04:22PM | Earnings Volatility Drives These Stocks in a New Direction at Wall St. Cheat Sheet |
| 09-May-13 05:14AM | Exelixis traders look for more gains optionMONSTER |
| 08-May-13 05:42PM | Exelixis Announces Webcasts of Upcoming Investor Conference Presentations Business Wire +7.41% |
| 04:35PM | EXEL Crosses Above Key Moving Average Level at TheStreet |
| 01:26PM | 3 Stocks to Get on Your Watchlist at Motley Fool |
| 07-May-13 11:07PM | Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:49PM | Exelixis Earnings: Heres Why the Stock is Up Now at Wall St. Cheat Sheet |
| 05:00PM | Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:18PM | InPlay: Exelixis beats by $0.05, beats on revs Briefing.com |
| 04:15PM | Exelixis Announces First Quarter 2013 Financial Results Business Wire |
| 04:13PM | Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting Business Wire |
| 09:20AM | EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 09:02AM | EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 07:07AM | Q1 2013 Exelixis, Inc. Earnings Release - After Market Close CCBN |
| 06-May-13 08:13PM | Exelixis Earnings: What Investors Should Watch at Wall St. Cheat Sheet |
| 03-May-13 05:15PM | 5 Reasons to Worry About Next Week at Motley Fool |
| 30-Apr-13 08:20PM | Here's What This $9 Billion Contrarian Has Been Buying at Motley Fool |
| 29-Apr-13 04:00PM | Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players at Motley Fool |
| 11:35AM | Large Market Opportunity in Hepatitis C from a Volume Perspective: Brian Skorney Discusses Pockets in the Hepatitis C Space Where Companies Other Than Gilead (GILD) Will See Value Wall Street Transcript |
| 24-Apr-13 10:38AM | A Former Google Exec Aims To Power A Patient Revolution at Forbes |
| 10:20AM | The Roth IRA Rules! at Motley Fool |
| 18-Apr-13 09:46AM | 2 Biotech Companies With Multi-Bagger Potential at Motley Fool |
| 17-Apr-13 06:13PM | Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call Business Wire |
| 04:18PM | 5 Stocks Begging for a Short Squeeze at Motley Fool |
| 16-Apr-13 06:43PM | Lightning Round: Dollar Tree, Toll Brothers & More at CNBC |
| 06:40PM | [video] Lightning Round at CNBC |
| 15-Apr-13 07:16AM | 5 of Last Week's Biggest Winners at Motley Fool |
| 14-Apr-13 07:54AM | The Best- And Worst-Performing Biotech Stocks, April 5 To April 12 at Forbes |
| 11-Apr-13 11:34AM | EXEL Crosses Above Key Moving Average Level at Forbes |
| 09-Apr-13 04:03PM | InPlay: Exelixis: Preclinical data presented at AACR describe a mechanism of action of cabozantinib in a prostate cancer bone metastasis model Briefing.com |
| 04:01PM | Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model Business Wire |
| 01-Apr-13 09:22AM | Where Is Exelixis In The Cancer Therapeutics Market? at Seeking Alpha |
| 24-Mar-13 04:30AM | Solving The R&D Investment Dilemma With Project Funding: Mark Kessel at Seeking Alpha |
| 20-Mar-13 02:57PM | Buy, Sell, or Hold: Exelixis at Motley Fool |
| 18-Mar-13 10:34PM | Here's What This 220% Gainer Has Been Buying and Selling at Motley Fool |
| 06-Mar-13 08:39AM | Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players at Motley Fool |
| 05-Mar-13 11:23PM | Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players at Motley Fool +5.07% |
| 03-Mar-13 10:39AM | Why Exelixis Is Ready to Rebound at Motley Fool |
| 28-Feb-13 05:04PM | Buy, Sell, or Hold: Opko Health at Motley Fool |
| 27-Feb-13 01:04PM | EXELIXIS, INC. Financials EDGAR Online Financials |
| 04:00AM | Exelixis Inc. Stock Downgraded (EXEL) at TheStreet |
| 26-Feb-13 08:20AM | U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Marketwire |
| 25-Feb-13 04:20PM | Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference Business Wire |
| 23-Feb-13 08:12PM | New Star Analyst Rankings for Exelixis, Inc. StarMine |
| 10:30AM | 5 Stocks Surprise Traders After Earnings at Wall St. Cheat Sheet |
| 08:02AM | A Fool Looks Back at Motley Fool |
| 22-Feb-13 07:26PM | New Star Analyst Rankings for Exelixis, Inc. StarMine -5.16% |
| 02:33AM | EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER Thomson Reuters ONE |
| 21-Feb-13 10:58PM | Exelixis' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 08:03PM | Exelixis Earnings: Everything You Must Know Now at Wall St. Cheat Sheet |
| 05:00PM | Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:46PM | Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:24PM | Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ European Distributor for Medullary Thyroid Cancer Business Wire |
| 04:20PM | EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:20PM | InPlay: Exelixis misses by $0.04, misses on revs Briefing.com |
| 04:18PM | Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results Business Wire |
| 04:14PM | Celgene's New Acquisition -- of Celgene at Motley Fool |
| 04:04PM | EXELIXIS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 07:07AM | Q4 2012 Exelixis, Inc. Earnings Release - After Market Close CCBN |
| 19-Feb-13 12:02PM | 5 Can't-Miss Health-Care Events This Week at Motley Fool |
| 09:44AM | Four Biotech Stocks On The Clock at Seeking Alpha |
| 15-Feb-13 10:12AM | 5 Reasons to Worry About Next Week at Motley Fool |
| 10-Feb-13 12:02PM | 5 Can't-Miss Health-Care Events This Week at Motley Fool |
| 08-Feb-13 07:04PM | Exelixis execs win bonuses, pay boosts as first cancer drug hits market at bizjournals.com |
| 05:22PM | EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online |
| 07-Feb-13 04:56PM | Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call Business Wire |
| 06-Feb-13 05:23PM | Exelixis Announces Webcast of February 12th Presentation at the 15th Annual BIO CEO & Investor Conference Business Wire |
| 02-Feb-13 06:38PM | What's Ahead for Exelixis? at Motley Fool |
| 31-Jan-13 01:06PM | Prognosis Positive: Medical Growth Stocks to Watch at Motley Fool |
| 30-Jan-13 04:56PM | Revisiting Exelixis And Cabozantinib at Seeking Alpha |
| 09:32AM | Buy, Sell, or Hold: Peregrine Pharmaceuticals at Motley Fool |
| 25-Jan-13 10:32PM | Here's a Basket of Potentially Explosive Growth at Motley Fool |
| 05:01PM | EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online |
| 24-Jan-13 11:48AM | InPlay: Exelixis announces COMETRIQ (cabozantinib) is now available in the U.S. Briefing.com |
| 11:47AM | Exelixis Announces COMETRIQ (cabozantinib) Is Now Available in the U.S. Business Wire |
| 23-Jan-13 03:53AM | Biotech: Core and Explore at Motley Fool |
| 03:38AM | One Biotech Pony, Lots of Tricks at Motley Fool |
| 18-Jan-13 05:33PM | Pipeline Advances at Exelixis Zacks |
| 17-Jan-13 08:21AM | Do Orphan Drug Developers Belong in Your Portfolio? at Motley Fool |
| 08:20AM | Biotech Industry Expected to Experience More M&A Activity in 2013 Marketwire |
| 16-Jan-13 05:02PM | EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online |
| 15-Jan-13 05:14AM | JPMorgan Healthcare Conference Highlights: Exelixis at Motley Fool |
| 05:04AM | 3 Highly Shorted Stocks Under $5 Being Snapped By Hedge Funds at Seeking Alpha |
| 09-Jan-13 10:28PM | Exelixis' CEO Presents at J.P. Morgan 31st Annual Healthcare Conference (Transcript) at Seeking Alpha |
| 04-Jan-13 10:56AM | 3 Biotech Stocks You Can Buy in 2013 at Motley Fool |
| 03-Jan-13 01:59PM | Labrys Bioscience, founded by Corey Goodman, snags Pfizer migraine drug, $31 million at bizjournals.com |
| 26-Dec-12 10:01AM | 3 Stocks Near 52-Week Lows Worth Buying at Motley Fool |
| 24-Dec-12 10:05AM | EXEL Trading Below Director's Recent Buy Price at Forbes |
| 22-Dec-12 06:23AM | 5 Medical Stock Losers From Last Week With High Short Ratios at Seeking Alpha |
| 21-Dec-12 03:25PM | 5 Reasons to Worry About 2013 at Motley Fool |
| 19-Dec-12 07:00AM | Shorting Alexza Pharma On FDA's Adasuve Approval at TheStreet |
| 17-Dec-12 10:58AM | Exelixis Rebounds From 'Sell The News' Reaction at Seeking Alpha |
| 14-Dec-12 05:19PM | EXELIXIS, INC. Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefit Plans EDGAR Online -5.80% |
| 13-Dec-12 04:27PM | What Are Insiders Buying Recently? at Motley Fool |
|
|
| Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MORRISSEY MICHAEL | President and CEO | May 15 | Option Exercise | 0.00 | 3,125 | 0 | 4,817 | May 17 07:21 PM | | Lamb Peter | EVP, Discovery Research & CSO | May 15 | Option Exercise | 0.00 | 3,124 | 0 | 28,589 | May 17 07:17 PM | | KARBE FRANK | EVP and CFO | May 15 | Option Exercise | 0.00 | 1,953 | 0 | 90,030 | May 17 07:17 PM | | SIMONTON PAMELA A | EVP and General Counsel | May 15 | Option Exercise | 0.00 | 1,875 | 0 | 15,503 | May 17 07:16 PM | | Schwab Gisela | EVP and Chief Medical Officer | May 15 | Option Exercise | 0.00 | 2,187 | 0 | 65,427 | May 17 07:17 PM | | SIMONTON PAMELA A | EVP and General Counsel | Feb 15 | Option Exercise | 0.00 | 1,875 | 0 | 14,507 | Feb 15 08:35 PM | | Lamb Peter | EVP, Discovery Research & CSO | Feb 15 | Option Exercise | 0.00 | 3,126 | 0 | 26,928 | Feb 15 08:34 PM | | MORRISSEY MICHAEL | President and CEO | Feb 15 | Option Exercise | 0.00 | 3,125 | 0 | 3,125 | Feb 15 08:34 PM | | Schwab Gisela | EVP and Chief Medical Officer | Feb 15 | Option Exercise | 0.00 | 2,188 | 0 | 59,062 | Feb 15 08:35 PM | | KARBE FRANK | EVP and CFO | Feb 15 | Option Exercise | 0.00 | 1,953 | 0 | 82,704 | Feb 15 08:33 PM | | MARCHESI VINCENT T | Director | Dec 20 | Buy | 4.68 | 4,000 | 18,720 | 25,000 | Dec 20 07:11 PM | | MARCHESI VINCENT T | Director | Dec 19 | Buy | 4.67 | 1,500 | 7,005 | 21,000 | Dec 19 07:49 PM | | MARCHESI VINCENT T | Director | Dec 18 | Buy | 4.82 | 1,500 | 7,230 | 19,500 | Dec 19 07:49 PM | | MARCHESI VINCENT T | Director | Dec 17 | Buy | 4.70 | 3,000 | 14,093 | 18,000 | Dec 19 07:49 PM | | Schwab Gisela | EVP and Chief Medical Officer | Dec 10 | Buy | 4.39 | 25,000 | 109,750 | 56,874 | Dec 10 08:25 PM | | Lamb Peter | EVP, Discovery Research & CSO | Nov 15 | Option Exercise | 0.00 | 5,209 | 0 | 25,348 | Nov 16 09:25 PM | | KARBE FRANK | EVP and CFO | Nov 15 | Option Exercise | 0.00 | 1,953 | 0 | 81,467 | Nov 16 09:25 PM | | MORRISSEY MICHAEL | President and CEO | Nov 15 | Option Exercise | 0.00 | 3,125 | 0 | 3,125 | Nov 16 09:26 PM | | SIMONTON PAMELA A | EVP and General Counsel | Nov 15 | Option Exercise | 0.00 | 1,875 | 0 | 13,319 | Nov 16 09:24 PM | | Schwab Gisela | EVP and Chief Medical Officer | Nov 15 | Option Exercise | 0.00 | 5,312 | 0 | 33,020 | Nov 16 09:25 PM | | MORRISSEY MICHAEL | President and CEO | Aug 15 | Option Exercise | 0.00 | 3,125 | 0 | 20,796 | Aug 17 07:42 PM | | Schwab Gisela | EVP and Chief Medical Officer | Aug 15 | Option Exercise | 0.00 | 2,188 | 0 | 29,312 | Aug 17 07:43 PM | | Lamb Peter | EVP, Discovery Research & CSO | Aug 15 | Option Exercise | 0.00 | 3,125 | 0 | 21,648 | Aug 17 07:42 PM | | SIMONTON PAMELA A | EVP and General Counsel | Aug 15 | Option Exercise | 0.00 | 1,875 | 0 | 12,131 | Aug 17 07:41 PM | | KARBE FRANK | EVP and CFO | Aug 15 | Option Exercise | 0.00 | 1,953 | 0 | 77,360 | Aug 17 07:41 PM | | MARCHESI VINCENT T | Director | Jun 14 | Sale | 5.13 | 7,000 | 35,911 | 15,000 | Jun 15 05:03 PM |
|
|
|
|
|
|
